Hear how a single ctDNA blood draw 3 to 9 weeks into immunotherapy may reveal response earlier than imaging in NSCLC, with Valsamo Anagnostou, MD, PhD.
|Videos|July 17, 2014
<em>ESR1</em> Mutations in Primary Breast Cancer
Author(s)Suzanne A. W. Fuqua, PhD
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discusses ESR1 mutations in primary breast cancer.
Advertisement
Clinical Pearls
Suzanne A. W. Fuqua, PhD, professor of medicine at Baylor College of Medicine, discussesESR1mutations in primary breast cancer.
- There is some controversy surrounding whether or notESR1mutations are associated with primary breast cancer.
- It has been reported that the K303R mutation was present in premalignant breast cancer as well as in primary breast tumors.
- Further research is needed to validate the presence and frequency of the K303R mutation in primary breast cancer.
Advertisement
Related to this article
Aman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.
Nikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.
Mark A. Lewis, MD, explains how oral cabozantinib reduces time toxicity for patients with previously treated, well-differentiated neuroendocrine tumors.
Amr Mohamed, MD, reviews zocilurtatug pelitecan phase 1/2 data in platinum-refractory extrapulmonary neuroendocrine carcinoma.
Halfdan Sorbye, MD, PhD, discusses why accurately distinguishing NET G3 from NEC is critical, as the wrong first-line therapy can shorten survival.
Chrisann Kyi, MD, discusses the 79.3% response rate with sofetabart mipitecan plus bevacizumab in platinum-sensitive ovarian cancer and phase 3 plans.
Hoth Therapeutics stopped the phase 2a CLEER-001 trial of topical HT-001 early after an interim review and will seek FDA input on phase 3.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves Amivantamab and Hyaluronidase for Recurrent/Metastatic HNSCC
2
Zocilurtatug Pelitecan Shows Activity in epNEC Across DLL3 Expression Levels
3
LITESPARK-011 Raises Questions About RCC Treatment Sequencing
4
Dr Mohamed on Zocilurtatug Pelitecan for Refractory Extrapulmonary NEC
5